The global high-content screening market size is projected to reach a valuation of US$ 3 billion by 2033. High-content screening is expected to see positive market growth and reach a total estimated value of more than US$ 1.6 billion in 2022. High-content screening demand is expected to rise significantly, as indicated by the 5.8% predicted CAGR in sales volume (units).
Cellomics and high content screening (HCS) are related terms. It is a technique used in biological research and drug discovery to find new drug candidates. Digital microscopy and flow cytometry are the main foundations of high-content screening systems, along with a combination of IT systems for the storage and analysis of biological data.
The pharmaceutical industry has found that high content screening techniques are very effective for characterizing preclinical drugs. This technology frequently coexists with a variety of other uses, like drug development. The use of HCS in conjunction with chemical genetics to study biological systems is expected to grow over the next few years.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-426
Key Takeaways
- The CAGR for the global market over the preceding period was 5.1%.
- Over the coming decades, the market in India is anticipated to grow at a CAGR of 6.6%.
- With more than 7.3% of all demand recorded in Europe in 2022, Germany has emerged as a major market.
- Over the coming decade, the market in China is anticipated to grow at a CAGR of 7.8%.
- The highest demand for High Content Screenings came from the pharmaceutical and healthcare industries.
“The rising prevalence of multiple infectious diseases with a variety of symptoms raises the demand for innovative treatments. As a result, there will be an increase in biotechnology and pharmaceutical study and development efforts to identify new drug candidates. Imaging technologies are becoming increasingly important in drug discovery and analysis.” says an FMI analyst.
Competitive Landscape
Key players in the HCS market employ strategies such as mergers and acquisitions, product launches, collaborations, and alliances to expand their businesses.
- Particle Works, a progressive company that creates and markets cutting-edge particle engineering platforms, declared the release of the Automated Library Synthesis (ALiS) System, a new ground-breaking platform, in November 2022. This innovative platform favors automation in the early stages of the creation of drugs as well as high-throughput evaluation of lipid nanoparticle (LNP) formulations and mRNA candidates.
- The Twist High Throughput Antibody Production platform, developed by California-based Twist Bioscience Corporation, was made public in April 2022. It allows customers to convert candidate genetic sequences into cleansed antibodies for use in a variety of applications related to screening and therapeutic discovery projects.
Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-426
Key Companies Profiled
- Thermo Fisher Scientific Inc.
- Becton Dickinson, and Company
- GE Healthcare
- Olympus Corporation
- PerkinElmer Inc.
- Sysmex Corporation
- Merck KGaA
- Danaher Corporation
- Yokogawa Electric Corporation
- BioTek Instruments Inc.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global high-content screening market presenting a historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights by product type (cell imaging & analysis, consumables, software, services), industry (pharmaceutical & healthcare, biotechnology, educational institutions, independent CROs, government organizations), application & region.
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
